“Toad Venom Psychedelic Shows Promise for Treatment-Resistant Depression in Clinical Trial” — what this page in the network covers. A new clinical trial has tested a psychedelic compound derived from toad venom on patients with treatment-resistant depression, yielding promising results that could open new avenues for mental health treatment. The study, reported by ScienceAlert, found that the compound, known as 5-MeO-DMT, produc The study, reported by ScienceAlert, found that the compound, known as 5-MeO-DMT, produced rapid and significant reductions in depressive symptoms among participants who had not responded to standard therapies.
While the exact mechanisms are still being investigated, researchers believe the substance may promote neuroplasticity and disrupt rigid patterns of negative thinking. However, many questions remain regarding long-term efficacy, safety, and optimal dosing. The findings highlight the growing interest in psychedelic-assisted therapy as a potential breakthrough for millions suffering from severe depression. The full version stays on the original page, which this listing opens directly.